# Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

> **NCT05445778** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 520 (estimated)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab soravtansine plus Bevacizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05445778
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-04
- **Final completion:** 2032-05
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445778, "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05445778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*